Von Willebrand disease is an inherited condition in which the blood does not clot properly, so bleeding takes longer than usual to stop, and it is the most common inherited bleeding disorder [1].
This page provides general information. It does not replace advice from a doctor or another qualified healthcare professional.
Von Willebrand disease is a condition in which the blood does not clot properly, so bleeding takes longer to stop [1]. It is the most common inherited bleeding disorder [1,9].
Von Willebrand factor is one of the proteins that makes blood clot. When a vessel is damaged it acts like glue, helping small blood cells called platelets stick together and seal the leak, and it also carries a second clotting protein, factor VIII [1,8]. People with the condition have too little of it, or a version that does not work [1].
There are three main types [1,5]:
The subtype matters, since treatment differs [1]. Acquired von Willebrand syndrome is a separate, non-inherited problem [1,5].
Two very different numbers appear in the literature. Both are correct, and they count different things.
The first is about 1 percent, or 1 in 100 people. It comes from studies that measured von Willebrand factor in large groups of ordinary people, giving figures of roughly 0.6 to 1.6 percent [9]. The Centers for Disease Control and Prevention puts it at up to 1 percent, or around 3.2 million people in the United States [1]. Most of them have only mildly reduced levels and may never need treatment [9].
The second number is about 1 in 1,000, or 0.1 percent. It counts people whose bleeding needs medical attention [8]. Orphanet puts disease needing specific treatment at about 1 in 10,000, stricter again, and type 3 is rare at 0.1 to 5.3 cases per million [9,10].
In short: low von Willebrand factor is common, disease causing real bleeding problems is much less common, and severe disease is rare.
Registry figures are lower again, averaging 25.6 recorded cases per million worldwide [9]. Registries count only people diagnosed and reported, so they reflect access to specialist laboratories more than true occurrence.
Genes are instructions inside our cells. Von Willebrand disease is caused by a change, often called a gene variant, in the VWF gene on chromosome 12, which carries the instructions for making von Willebrand factor [5,10].
Most cases of types 1 and 2 follow an autosomal dominant pattern: one changed copy, from either parent, is enough, so each child of an affected parent has a 1 in 2 chance [5,8]. Type 3 and some type 2 cases are autosomal recessive, meaning both copies must be changed. Each parent then carries one changed copy, usually without symptoms, and each child has a 1 in 4 chance [5,8].
Sometimes there is no family history, since the change can happen newly before birth [1]. People with blood group O have naturally lower levels, which can make test results harder to read [8,10].
Symptoms depend on the type and on how low the levels are, and some people have almost none. The usual pattern is bleeding from the skin and from the moist linings of the nose, mouth and gut [7,8].
Common signs include [1,8]:
Heavy menstrual bleeding is the most common reason women come forward, reported by 95 percent of women with the condition in one study, and it often leads to low iron and then anemia [2,8].
When to seek urgent help. Seek medical care, or contact your treatment center, for bleeding that will not stop, bleeding that restarts after surgery or dental work, a blow to the head, blood in the stool or urine, or heavy bleeding after childbirth [8]. Bleeding can occasionally damage joints or organs, so it is reasonable to ask for help early [1].
Diagnosis usually starts with a family doctor, a gynecologist or a pediatrician asking about personal and family bleeding history [1]. Joint guidelines from four international bleeding disorder organizations recommend a validated bleeding-history questionnaire where the condition seems unlikely, and blood tests straight away where it seems likely [6].
Routine clotting tests are often normal, so they cannot rule it out. The specific tests are [3]:
The 2021 guidelines confirm type 1 below 0.30 IU/mL, or below 0.50 IU/mL in someone who bleeds abnormally, and genetic testing is used for subtypes 2B and 2N [6]. Tests often need repeating, since levels rise with stress, infection, pregnancy and some hormonal medicines [3,8]. Diagnosis is often delayed: in one survey women waited an average of 16 years from first symptoms to diagnosis [2].
There is no cure [13]. Treatment raises von Willebrand factor when needed, or helps clots hold. Many people with mild disease need treatment only around surgery, dental work or childbirth [8].
Desmopressin. Desmopressin, or DDAVP, prompts the body to release its own stored von Willebrand factor and factor VIII. Given by injection or nasal spray, it works well for many people with type 1, and guidelines recommend a trial dose first [1,7,8]. It is not used in type 3, where there is nothing stored to release, and is avoided in type 2B [7,8].
Von Willebrand factor concentrates. These replace the missing protein, given into a vein. Some come from donated plasma, and one is made in a laboratory [1,8]. They are the main treatment for type 3, most of type 2, and serious bleeding or major surgery in any type [8].
Antifibrinolytics and hormonal options. Tranexamic acid and aminocaproic acid help hold a clot in place rather than form one, and suit bleeding from the nose, mouth, gut and womb [1,8]. For heavy periods, guidelines suggest combined hormonal contraception or a levonorgestrel-releasing intrauterine device for women who do not wish to conceive, and tranexamic acid for those who do [7]. Iron should be checked and treated [7,8].
Surgery, childbirth and prevention. For major surgery, guidelines suggest keeping von Willebrand factor and factor VIII activity at 0.50 IU/mL or above for at least three days afterward, and tranexamic acid after delivery [7]. For severe and frequent bleeds, long-term preventive concentrate is suggested [7,8]. Concentrates and specialist testing are far less accessible in low-income countries [9].
Most people live full lives with little day-to-day disruption [8,13]. Care works best through a bleeding disorder treatment center, where hematology, gynecology and laboratory expertise sit together [7,8].
Carry details of the diagnosis and treatment plan, and consider a medical bracelet so emergency staff know quickly [8]. Check medicines with a doctor, since aspirin and anti-inflammatory painkillers interfere with clotting [8]. Contact your center before any surgery, dental procedure or pregnancy [8].
Pregnancy needs planning. Levels rise for some people and not others, so third-trimester blood tests help, and care should be shared between the obstetric team and a bleeding disorder center [4,7,8]. Bleeding after birth is a genuine risk, since clotting factor levels drop quickly once the baby is born [4].
Clinical trials are research studies that test whether a treatment works and is safe. Von Willebrand disease is an active research area, so studies come up reasonably often. Deciding whether to look into one is a personal choice, and it helps to take it in steps.
It is worth being clear on what a study actually involves:
Every trial has rules about who can take part. These are called eligibility criteria. Some describe who can join, and others who cannot. For a von Willebrand disease study they might include a confirmed diagnosis with laboratory results, a particular type or subtype such as type 3 or type 2B, a von Willebrand factor level below a set figure, a number of bleeding episodes in the past year, an age range, and whether someone already receives preventive treatment.
trialport’s medifit helps people consider information related to possible medical suitability. It does not diagnose a condition, confirm eligibility or replace formal screening by the study team.
Explore von Willebrand disease clinical trials through trialport
Medical suitability is only part of the picture. A study can look right on paper and still be hard in practice. Worth thinking through:
trialport’s readifit helps people reflect on their understanding, motivation, time, routines, support, emotions and practical arrangements.
Useful questions to put to a research team:
Taking part is voluntary. A person can ask questions, speak with people they trust and choose not to participate.
Search for clinical trials at app.trialport.com.
Research covers several areas:
Study status checked: 3 August 2026. Research moves and what is being studied changes, so this list will date. For current information, search at app.trialport.com.
Internationally, the World Federation of Hemophilia publishes plain-language booklets and a directory of member organizations and treatment centers by country, the most practical starting point outside the US, UK and Canada [8]. In the United States, the National Bleeding Disorders Foundation links to treatment centers [12], and the Centers for Disease Control and Prevention pages cover diagnosis and pregnancy [1,4]. In the United Kingdom, The Haemophilia Society publishes an Understanding von Willebrand Disease booklet [13], and in Canada the Canadian Hemophilia Society has regional chapters [14]. The 2021 joint guidelines and the older National Heart, Lung, and Blood Institute report are free to read [6,7,11]. Coverage elsewhere is uneven, and provision in low-income countries is thin [9].
Is it the same as hemophilia?
No. Both are inherited bleeding disorders, though von Willebrand disease is far more common, affects men and women equally, and usually causes bleeding from the skin and linings rather than into joints [1,8].
Can men have it?
Yes, roughly equally. Women are more likely to notice symptoms because of periods, pregnancy and childbirth, which is part of why they are often diagnosed later [1,2].
Are heavy periods always a sign of a bleeding disorder?
No, there are many other causes. Repeated heavy periods with low iron are worth raising with a doctor [2,8].
Can it be cured?
No, though bleeding can usually be prevented or controlled with desmopressin, concentrates, tranexamic acid or hormonal treatment [7,8,13].
Will my children inherit it?
It depends on the type. With the dominant types each child of an affected parent has a 1 in 2 chance, and with the recessive types a 1 in 4 chance [8].
Written by: trialport editorial team
Reviewed by: Keith Berelowitz, Founder and CEO, trialport
Reviewed on: 3 August 2026
Next review due: 3 August 2027
References last checked: 3 August 2026